Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Accepts Fewer Side Effects In Recommending Sanofi-Aventis's Multaq

This article was originally published in The Pink Sheet Daily

Executive Summary

Second draft appraisal of Multaq recommends use in atrial fibrillation, even though the drug is less effective than other anti-arrhythmics

You may also be interested in...



NICE Issues Favorable Final Draft Guidance On Sanofi-Aventis' Multaq

NICE's final appraisal determination on Sanofi-Aventis' Multaq recommends limited use in U.K. atrial fibrillation patients. In France, more favorable ratings by the Transparency Commission might mean a better price.

NICE Issues Favorable Final Draft Guidance On Sanofi-Aventis' Multaq

NICE's final appraisal determination on Sanofi-Aventis' Multaq recommends limited use in U.K. atrial fibrillation patients. In France, more favorable ratings by the Transparency Commission might mean a better price.

FDA Social Media Group Reviewing Its First iPhone App As DTC Marketing Tool, But It's Not The First To Be Released

FDA has started wading into the iPhone business, at least to help determine how drug companies can use the App Store. FDA's social media working group is reviewing its first submission for an iPhone app as a direct-to-consumer marketing tool, Division of Drug Marketing, Advertising and Communications special assistant Jean-Ah Kang told the DTC National Conference April 9

Related Content

Topics

UsernamePublicRestriction

Register

PS070470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel